Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetically Modified DC-CIK for Relapsed Acute Leukemia
NCT01956630Phase 2Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- Sep 2013
- Primary completion
- Sep 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of unmodified CIK in acute leukemia, sponsored by Academy of Military Medical Sciences. Status: unknown.
02
Drugs
unmodified CIK
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT01956630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01956630.